Dade improved VRSA test:
This article was originally published in Clinica
Executive Summary
Dade Behring has received US FDA 510(k) clearance to market an enhanced version of its automated method for detecting vancomycin-resistant Staphylococcus aureus (VRSA). The Deerfield, Illinois company has developed an improved formulation of vancomycin to detect VRSA on its MicroScan dried gram-positive, overnight, antimicrobial susceptibility test panels. Dade, which has nearly 60 MicroScan panels of tests, with up-to-date antibiotics including overnight, rapid and specialty panels, said it was in the process of incorporating the new formulation of vancomycin into the entire product line of MicroScan dried gram-positive, overnight, panels sold globally. The new formulation is anticipated to be available in all of the existing configurations by the autumn of 2005.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.